Tests NKT3964 pill in adults with advanced solid tumors
Tests the oral drug NKT3964 for safety in adults with advanced solid tumors.
Key facts
- Who runs it
- NiKang Therapeutics, Inc.
- Where
- Atlanta, Augusta, Austin, Boston, Charlottesville, Dallas, Denver, Fairfax, Fairway, Hackensack, Lake Mary, Little Rock, Los Angeles, Nashville, Orlando, Philadelphia, Pittsburgh, Salt Lake City, and San Francisco, United StatesSee the 19 sitesAlso in 1 other country, 2 sites
- Trial code
- Registry title
- A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 238 people, planned
- Started
- 19 Sept 2024
- Expected to end
- May 2029
- Type of study
- Interventional, 10 groups
- Treatments tested
- NKT3964
- Paclitaxel
- Doxorubicin
- Record updated
- 5 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with advanced or metastatic solid tumors, such as ovarian, endometrial, gastric, small cell lung or breast cancer, whose disease has progressed on standard treatment.
- Age
- 19 years or older
- Sex
- All sexes can join.
- Disease stage
- Advanced and unresectable or metastatic solid tumor with documented progression on the last standard treatment. Tumor types include ovarian, endometrial, gastric/gastroesophageal junction/esophageal adenocarcinoma, small cell lung cancer, triple-negative breast cancer, and HR+/HER2- breast cancer.
- Earlier treatment
- People must have progressed on, or not tolerated, existing therapy known to help their condition. The number of prior treatment lines is capped in some groups (for example ≤4 lines in ovarian and endometrial groups). HR+/HER2- breast cancer must have progressed after a CDK4/6 inhibitor. Prior CDK2 inhibitor or degrader treatment is not allowed.
- Biomarker or test result
- CCNE1 amplification is needed for several groups, including gastric, esophageal, endometrial, ovarian expansion groups and other solid tumors. The record names this test result as a requirement.
Main reasons for not taking part
- Locally advanced tumor that can be treated with radical surgery, radiotherapy or chemotherapy
- Known active brain or CNS metastases, or carcinomatous meningitis
- Known HIV, or active hepatitis B or C infection
- History of uveitis, retinopathy or significant corneal or retinal disease
- Clinically significant cardiovascular event within 6 months before starting NKT3964
The registry criteria, word for word
Show all 29 criteriaShow less
Who can take part
- Must have a pathologically confirmed advanced and unresectable or metastatic solid tumor listed below with documented disease progression on last standard treatment. Part 1 Monotherapy Dose Escalation (including Food Effect Sub-study): subjects must be refractory to, or intolerant of existing therapy(ies) known to provide clinical benefit for their condition; Part 1 Monotherapy Dose Escalation:
- Ovarian cancer
- Endometrial cancer (only endometrioid subtype will require CCNE1 amplification)
- Gastric, gastroesophageal junction (GEJ) or esophageal adenocarcinoma with CCNE1 amplification
- Small cell lung cancer (SCLC)
- Triple-negative breast cancer (TNBC; HER2, estrogen receptor and progesterone receptor negative)
- HR+ (includes estrogen-receptor or progesterone-receptor) and HER2- breast cancer (must have progressed following treatment with a CDK4/6 inhibitor, and is not suitable for endocrine therapy [ET])
- Other solid tumors with CCNE1 amplification; - Part 2 Monotherapy Dose Expansion:; Part 2A: HR+ and HER2- breast cancer that is locally advanced and unresectable (Stage III) or metastatic (Stage IV); previously treated with ≥1 line of standard of care (SOC) including CDK4/6 inhibitor plus ET and not suitable for further ET. Subjects must have progressed after receiving therapy for ≥3 months in the metastatic setting or for ≥6 months in the adjuvant setting. Subjects must have received ≤2 lines of systemic cytotoxic therapy (chemotherapy or cytotoxic antibody drug conjugate [ADC]) in the metastatic setting; Part 2B: Advanced platinum-based-chemotherapy resistant or refractory epithelial ovarian/fallopian/primary peritoneal carcinoma or clear cell ovarian cancer (defined as recurrence ≤6 months after completing platinum-based regimen) with progression on at least one platinum containing therapy and previously treated with ≤4 prior lines of systemic therapy administered for advanced/metastatic disease and with CCNE1 amplification; Part 2C: Advanced unresectable or metastatic gastric, GEJ or esophageal adenocarcinoma with progression on at least one systemic therapy and previously treated with ≤3 prior lines of systemic therapy administered for advanced/metastatic disease, with CCNE1 amplification; Part 2D: Advanced endometrial adenocarcinoma or uterine papillary serous carcinoma previously treated with ≤4 prior lines of systemic therapy administered for advanced/metastatic disease with CCNE1 amplification. Subjects with clear cell carcinoma or uterine serous carcinoma histology may be considered regardless of CCNE1 status after discussion and approval from the Sponsor; Part 2E: Advanced/recurrent uterine carcinosarcoma previously treated with 1 prior platinum-based chemotherapy regimen and ≤3 prior lines of systemic therapy. Prior bevacizumab or PARP inhibitors are allowed and must be at least 3 weeks prior to the start of study drug; -Part 3 Combination Dose Escalation:; Advanced endometrial adenocarcinoma or uterine papillary serous carcinoma previously treated with ≤4 prior lines of systemic therapy administered for advanced/metastatic disease with CCNE1 amplification. (Subjects with clear cell carcinoma or uterine serous carcinoma histology may be considered regardless of CCNE1 status after discussion and approval from the Sponsor); -Part 4 Combination Dose Expansion:; Advanced endometrial adenocarcinoma or uterine papillary serous carcinoma previously treated with ≤4 prior lines of systemic therapy administered for advanced/metastatic disease with CCNE1 amplification. (Subjects with clear cell carcinoma or uterine serous carcinoma histology may be considered regardless of CCNE1 status after discussion and approval from the Sponsor); Have adequate organ function; Subjects with female reproductive organs must be surgically sterile, post-menopausal, or must be willing to use highly effective method(s) of contraception; Ability to swallow oral medications; Consent to provide archived tumor tissues and paired tumor biopsy at pretreatment
Who cannot take part
- Locally advanced solid tumor that is a candidate for curative treatment through radical surgery and/or radiotherapy, or chemotherapy
- Failed to recover from effects of prior anticancer treatment therapy to baseline or Grade ≤ 1 severity (per CTCAE)
- Clinically significant cardiovascular event within 6 months prior to start of NKT3964 treatment
- Active wound healing from major surgery within 1 month or minor surgery within 10 days before the first dose of NKT3964
- Prior investigative treatment with a selective or nonselective CDK2 inhibitor or degrader
- Palliative radiation therapy within 14 days or other radiation therapy within 4 weeks prior to C1D1
- Prior severe hypersensitivity reaction to paclitaxel or other drugs formulated in Polyoxyl 35 Castor Oil (Cohort 3A and 4A only) or severe hypersensitivity reaction to doxorubicin or any other component of the product, other anthracyclines or anthracenediones (Cohort 3B and 4B)
- History of another malignancy with exceptions
- History of lymphohistiocytic or lymphoid hyperplasia; hemophagocytic lymphohistiocytosis
- Active interstitial lung disease currently requiring treatment
- History of uveitis, retinopathy or other clinically significant retinal disease
- Active or chronic corneal disorders, other active ocular conditions requiring ongoing therapy, or any clinically significant corneal disease
- Known human immunodeficiency virus (HIV), active hepatitis B or C infection
- Childs-Pugh class B or C cirrhosis or any other clinically significant liver disorder
- Active cardiac conditions including myocarditis, pericarditis, or clinically significant valvular heart disease
- Known elevated cardiac biomarkers at baseline
- History of anthracycline-related cardiomyopathy regardless of recovery
- Left ventricular ejection fraction (LVEF) <50% as measured by echocardiogram (ECHO) or multigated acquisition (MUGA) scan within 4 weeks prior to first dose
- Known active CNS metastases and/or carcinomatous meningitis
- - For subjects in Cohort 3B or 4B only:
- Cumulative lifetime exposure to doxorubicin, including planned doxorubicin in Part 3b or Part 4b, exceeding 450 mg/m2
Where in United States
Also in 1 other country, 2 sites
- Emory Winship Cancer InstituteAtlanta, United StatesContact: Winship ReferralsTaking people
- Augusta UniversityAugusta, United StatesContact: Bunja Rungruang, MD (principal investigator)Taking people
- NEXT OncologyAustin, United StatesContact: Suhrutha BushanTaking people
- Dana-Farber Cancer InstituteBoston, United StatesContact: Elizabeth Lee, MDTaking people
- University of VirginiaCharlottesville, United StatesContact: Chrystal AxfordTaking people
- UT SouthwesternDallas, United StatesContact: David Miller, MDTaking people
- SCRI at HealthOneDenver, United StatesContact: Front DeskTaking people
- NEXT VirginiaFairfax, United StatesContact: Maybelle De La RosaTaking people
- University of KansasFairway, United StatesNo longer taking part
- John Theurer Cancer Center At Hackensack UMCHackensack, United StatesContact: Oncology Clinical Research Referral OfficeTaking people
- Florida Cancer Specialists & Research InstituteLake Mary, United StatesNo longer taking part
- University of Arkansas Medical SchoolLittle Rock, United StatesContact: Maroof Zafar, MDTaking people
- University of California, Los AngelesLos Angeles, United StatesContact: Stacy ZamoraTaking people
- Sarah Cannon Research Institute SCRINashville, United StatesContact: Kate HallTaking people
- AdventHealth Cancer InstituteOrlando, United StatesContact: Advent Health Oncology ResearchTaking people
- Sidney Kimmell Cancer Center - Jefferson HealthPhiladelphia, United StatesContact: Sarah Cannon Research InstituteTaking people
- UPMCPittsburgh, United StatesNo longer taking part
- Intermountain HealthSalt Lake City, United StatesContact: Joshua Kunz, MDTaking people
- UCSFSan Francisco, United StatesNo longer taking part
About the trial
What the trial wants to find out
The goal of the Monotherapy Dose Escalation phase (Part 1) of the study is to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity to determine the preliminary recommended dose for expansion (RDE) of NKT3964 in adults with advanced or metastatic solid tumors.
Read full original descriptionShow less
The goal of the Monotherapy Expansion phase of the study (Part 2) is to evaluate the preliminary anti-tumor activity of NKT3964 at the RDE based on objective response rate (ORR) and determine the preliminary recommended Phase 2 dose (RP2D).
The goal of the Combination Dose Escalation phase (Part 3) of the study is to identify the RDE of NKT3964 in combination with chemotherapy in adult subjects with advanced/metastatic endometrial cancer. The goal of the Combination Expansion phase of the study (Part 4) is to evaluate the preliminary anti-tumor activity of NKT3964 in combination with chemotherapy at the RDE based on ORR.
The 10 groups in the trial
- Monotherapy Dose Expansion 2ATreatment being tested
Monotherapy Dose expansion 2A will include the RDE selected to determine the preliminary antitumor activity and the RP2D in HR+/HER2- breast cancer
Treatment: NKT3964
- Combination Dose Expansion 4ATreatment being tested
Combination Dose expansion 4A will evaluate the preliminary anti-tumor activity of NKT3964 in combination with chemotherapy (Paclitaxel) at the RDE from Part 3 based on ORR
Treatment: NKT3964 and Paclitaxel
- Combination Dose Expansion 4BTreatment being tested
Combination Dose expansion 4B will evaluate the preliminary anti-tumor activity of NKT3964 in combination with chemotherapy (Doxorubicin) at the RDE from Part 3 based on ORR
Treatment: NKT3964 and Doxorubicin
- Monotherapy Dose Expansion 2BTreatment being tested
Monotherapy Dose expansion 2B will include the RDE selected to determine the preliminary antitumor activity and the RP2D in CCNE1-amplified ovarian cancer
Treatment: NKT3964
- Monotherapy Dose Expansion 2CTreatment being tested
Monotherapy Dose expansion 2C will include the RDE selected to determine the preliminary antitumor activity and the RP2D in CCNE1-amplified upper gastrointestinal adenocarcinoma cancer
Treatment: NKT3964
- Monotherapy Dose Expansion 2DTreatment being tested
Monotherapy Dose expansion 2D will include the RDE selected to determine the preliminary antitumor activity and the RP2D in endometrial cancer
Treatment: NKT3964
- Monotherapy Dose Expansion 2ETreatment being tested
Monotherapy Dose expansion 2E will include the RDE selected to determine the preliminary antitumor activity and the RP2D in uterine carcinosarcoma
Treatment: NKT3964
- Monotherapy Dose EscalationTreatment being tested
Dose escalation will assess the safety, efficacy, and PK/PD data of oral dosing NKT3964 at increasing dosage levels to determine the MTD and/or preliminary RDEs.
Treatment: NKT3964
- Combination Dose Escalation 3ATreatment being tested
Combination Dose escalation Part 3A will evaluate the safety, tolerability, PK, and preliminary antitumor activity as well as determine the MTD and/or the preliminary RDE of NKT3964 in combination with chemotherapy (Paclitaxel) in endometrial cancer.
Treatment: NKT3964 and Paclitaxel
- Combination Dose Escalation 3BTreatment being tested
Combination Dose escalation Part 3B will evaluate the safety, tolerability, PK, and preliminary antitumor activity as well as determine the MTD and/or the preliminary RDE of NKT3964 in combination with chemotherapy (Doxorubicin) in endometrial cancer.
Treatment: NKT3964 and Doxorubicin
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 1, First-in-human, Open-label Study to Evaluate the Safety, Tolerability, PK, and Preliminary Anti-tumor Activity of the Novel Oral CDK2 Degrader NKT3964 in Adults With Advanced/Metastatic Solid Tumors
- Plain-language title
- Tests NKT3964 pill in adults with advanced solid tumorsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 5 November 2026